secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K/A
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001140361-24-002903
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics reports CEO transition and Nasdaq audit committee non-compliance
--------------------------------------------------------------------------------

- Dr. Han Ying appointed CEO effective Jan 15, 2024, succeeding retired Dr. Charles Wu.
- Employment agreement: $350K base salary, annual bonus, severance with 12-month salary, COBRA, and equity acceleration.
- Audit committee vacancy after Ying's departure; Nasdaq notified of non-compliance with Listing Rule 5605.
- Cure period runs until earlier of next annual meeting or July 15, 2024 to restore compliance.
- Dr. Renate Parry appointed Chair of Compensation Committee, replacing Dr. Han Ying.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/ef20019132_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-002903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer